The Role of the Thymus in Type I Diabetes. (TregDiab)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03236558|
Recruitment Status : Unknown
Verified October 2017 by University Hospital, Toulouse.
Recruitment status was: Not yet recruiting
First Posted : August 2, 2017
Last Update Posted : October 26, 2017
|Condition or disease||Intervention/treatment||Phase|
|Type1 Diabetes||Procedure: Blood collection||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Thymic Generation of Regulatory T Lymphocytes in Type I Diabetes Patients.|
|Estimated Study Start Date :||February 2018|
|Estimated Primary Completion Date :||February 2019|
|Estimated Study Completion Date :||February 2019|
Experimental: Patients with diabetes
T1D patients with blood collection
Procedure: Blood collection
Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
- Variability of the diversity of antigen-receptors' repertoires, expressed by regulatory T cells from type I diabetes patients and healthy controls. [ Time Frame: Day 1 ]Treg from the pediatric patients and the control subjects' blood will be isolated by cytometry, the messenger ribonucleic acid (mRNA) of these cells will be isolated, and the analysis of the alpha and beta chains of the TCRs will be carried out by high-throughput sequencing.
- Ratio between TCR diversities expressed by Treg cells vs. conventional T cells. [ Time Frame: Day 1 ]Treg from the pediatric patients and the control subjects' blood will be isolated by cytometry, the mRNA of these cells will be isolated, and the analysis of the alpha and beta chains of the TCRs will be carried out by high-throughput sequencing.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03236558
|Contact: Claire Le Tallec, MD||5 34 55 85 79 ext firstname.lastname@example.org|
|Contact: Françoise Auriol||5 67 77 10 95 ext email@example.com|
|CHU de Toulouse||Not yet recruiting|
|Toulouse, Midi-Pyrénées, France, 31059|
|Contact: Claire Le Tallec, MD 5 34 55 85 79 ext 33 firstname.lastname@example.org|
|Contact: Françoise Auriol 5 67 77 10 95 ext 33 email@example.com|
|Principal Investigator: Claire Le Tallec, MD|
|Sub-Investigator: Carole Morin, MD|
|Sub-Investigator: Zeina Ajaltouni, MD|
|Principal Investigator:||Claire Le Tallec, MD||CHU Toulouse|